Current Pathology modules within LIMS are not designed for working with whole slide images. Pathologists must purchase a Whole Slide Image Viewer as well as their LIMS system to perform digital reviews. Such applications offer a subpar experience, with laggy interfaces, and only allow you to view one image at a time.
Replace your expensive, outdated LIMS pathology module with the purpose-built Patholytix Data Capture Module for the ultimate pathology reporting experience. Score directly on images, avoid errors that arise from looking back and forth between two systems, and work more ergonomically.
Review & score studies on the same platform as whole slide images. All findings are automatically associated with the relevant slide. There’s no risk of human error in data input. Less work involved, since you won’t have to manually match a slide with its findings in the LIMS systems.
Findings can be viewed as text in the Study Grid, or geo-located to exactly where the finding is in the slide - a capability not possible with old Viewer + LIMS system workflows.
Patholytix overcomes the limits of LIMS, which commonly only accommodate toxicology studies. Not only does 3.0 offer enhanced scoring capabilities for safety assessment studies, but it also offers scoring templates for drug discovery studies such as tissue-cross reactivity (TCR), target-tissue characterisation (TTC), and dose-range finding (DRF) studies.
For the first time, users conducting discovery studies can reap the time-saving benefits associated with digital workflow.
Patholytix 3.0 offers superior data capture capabilities compared to any other platforms.
Scoring Data is captured in accordance with SEND / INHAND glossaries. Scoring in this format enables easy transcription into pathology reports and other systems with no additional overhead. Data is output in a form that facilitates report creation.
In Patholytix, you can score on the image in a specific region (geo-located findings). This capability is not possible in any other LIMS. This gives you flexibility in how you score (in the WSI viewer screen or in the grid screen).
With the new scoring capabilities and real-time sync of inputted data, users can score the same study from two different locations and the new scores will be reflected immediately. This is a workflow that was not possible before.
The quicker the review is completed, the quicker a decision can be made on the safety of the drug.
Patholytix allows users to keep their study findings, be they for glass, digital or hybrid studies, all in one place.
This allows you to begin your review immediately using the glass slides while waiting for slides to be scanned. This also means you don’t have to depend on any LIMS to record the findings from your glass slides. You can input these findings in the same place as for your digital slides.
This is a more organised way of working.
Once primary review is complete, results can be immediately shared with your partner organisation.
There’s no sorting, counting, or checking slides for breaks. Findings are inputted to Patholytix associated with its WSI. The primary review pathologist emails the peer review pathologist once complete. The peer review pathologist begins review.
There’s no waiting for shipment, no Customs declarations or permits, no set up of integration with LIMS. No inputting of findings into a separate LIMS system. No export of LIMS report. Patholytix scoring data is exported in a manner which makes report creation easy.
Patholytix is the first platform to enable digital review of non-clinical GLP studies. Digital eliminates a vast amount of work (sorting, counting slides, shipping, documentation). Digital is 42% faster than microscope.
Without a workflow being GLP compliant, a compound cannot progress to clinical trials. For the first time, you can maintain end-to-end compliance during your digital non-clinical study review.
Learn how the Patholytix Data Capture Module can help you make critical decisions in drug safety assessment more efficiently
SPEED UP YOUR REVIEWS AND DRUG DEVELOPMENT TIME
REVIEW & SCORE DRUG DISCOVERY STUDIES DIGITALLY FOR THE FIRST TIME
ACHIEVE IMAGE QUALITY AT SPEEDS BEYOND HUMAN CAPABILITIES
REACH CRITICAL DECISIONS FASTER, AND WITH GREATER CONFIDENCE
END-TO-END GLP-COMPLIANT DIGITAL STUDIES (A WORLD FIRST)
UNLOCK HISTORICAL PATHOLOGY KNOWLEDGE